Rivastigmine is generic equivalent to Novartis’ Exelon capsules.
Rivastigmine is indicated for use in the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s and Alzheimer’s diseases.
Teva commercial director Kim Innes said the company is making more medicines accessible for more people with the launch of Rivastigmine capsules.
"So far this year, we’ve launched 20 new products, including ten day-one patent expiries, which is good for Pharmacy because new products provide opportunities for increasing margins and keeping costs down," Innes added.
"But, more importantly it also means we continue to help save the NHS over £9bn a year."